PURPOSE: To
report the effects of combined low
dose bevacizumab and low
dose triamcinolone intravitreal injection compared with single
bevacizumab intravitreal injection in
patients with
macular edema secondary to
branch retinal vein occlusion .
METHODS: Thirty
eyes of 30
patients diagnosed with
branch retinal vein occlusion were evaluated. The combined
injection group (15
eyes of 15
patients ) was treated with
intravitreal injection of combined low
dose bevacizumab (0.625 mg/0.025 mL) and low
dose triamcinolone (1 mg/0.025 mL). The single
injection group (15
eyes of 15
patients ) was treated with
intravitreal injection of
bevacizumab (1.25 mg/0.05 mL). The best-corrected
visual acuity (BCVA), central macular thickness (CMT), and
intraocular pressure (IOP) of treated
eyes were measured before
injection and at 1 month, 2 months, and 3 months after
injection .
RESULTS: In the combined
injection group, the BCVA increased significantly at 1 month, 2 months, and 3 months after
injection (p 0.05) in both groups. The BCVA, CMT, and IOP after
injection showed no significant differences between the combined
injection group and the single
injection group (p > 0.05).
CONCLUSIONS: The combined
intravitreal injection of low
dose bevacizumab and low
dose triamcinolone may be useful and safe for the
treatment of
macular edema secondary to
branch retinal vein occlusion .